BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA
Athersys Coronavirus COVID-19

Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA

April 2, 2020 By Cade Hildreth (CEO) 1 Comment

Headquartered in Cleveland, Ohio, Athersys is a biotech company focused on the development of novel cell therapeutics. With acute respiratory distress syndrome (ARDS) identified as a leading cause of death in COVID-19 patients, Athersys is working fast to launch a pivotal trial of its MultiStem® cell therapy product for the treatment of this life-threatening condition.

Discover class-defining bioproduction tools.

MultiStem® is the company’s allogeneic “off-the-shelf” bone marrow-derived stem cell product for the treatment of ARDS.

In January 2020, as COVID-19 cases began to spread beyond China and into other nations worldwide, Athersys was approached by the Biomedical Advanced Research and Development Authority (BARDA). BARDA is a U.S. Department of Health and Human Services office responsible for countermeasures against global threats, including but not limited to bioterrorism, pandemics and emerging diseases.

bitbio

As a result of these interactions, Atherys’ MultiStem® cell therapy was designated as a “Highly Relevant” therapeutic for COVID-19 by BARDA.

Scalability of Athersys’ MultiStem® Cell Therapy

As noted by Athersys, “After isolation from a qualified donor, the MultiStem product may be expanded on a large scale, unlike other cell types, for future clinical use and stored frozen until needed. Cells obtained from a single donor undergo no genetic manipulation or modification and may be used to produce banks yielding hundreds of thousands to millions of doses of the MultiStem product.”

Pluristyx

This scalability makes MultiStem an intriguing approach to managing the health complications related to the global outbreak of COVID-19. Previously, Athersys has reported positive outcomes in other studies using its MultiStem therapy for the treatment of respiratory disease.

As explained by Dr. Gil Van Bokkelen, Chairman and CEO of Athersys:

“Throughout all of 2019, we made important progress in our key clinical programs in stroke and in other areas, as evidenced by the highly promising clinical results from our ARDS program. Those results led to the subsequent Fast Track designation from the FDA. The importance of this program has been reinforced by the recent COVID-19 outbreak, where many patients have subsequently become critically ill with ARDS, which a recent WHO analysis has confirmed is the primary cause of death for these patients.”

Athersys Milestones Related to ARDS

To date, Athersys has achieved several milestones related to the treatment of ARDS, including:

iPSC-derived cardiomyocte therapy
  • Completed its exploratory clinical study of MultiStem cell therapy for ARDS and announced positive 28-day and one-year results; MultiStem treated patients reported consistent improvement in quality of life over the one-year evaluation period and showed marked improvements in key clinical metrics, including ICU-free days, ventilator-free days and reduced mortality compared to placebo, especially in patients with pneumonia-induced ARDS
  • Advanced through Japanese partner, HEALIOS K.K., its ARDS and ischemic stroke programs, with Healios expecting to finish enrollment of both its ONE-BRIDGE ARDS study and the TREASURE stroke study this year
  • Athersys’ ARDS program received Fast Track designation from the U.S. FDA
  • Healios ARDS program, using HLCM051 (as the MultiStem cell therapy is designated in Japan), received orphan regenerative medicine designation in Japan

While there is not yet an approved treatment for COVID-19, the scientific, medical and regulatory communities are making heroic efforts to bring out new medicines. Athersys is one of more than a dozen cell therapy companies entering the race to find treatments approaches to the coronavirus and its complications.

To learn more, view the market report, “Coronavirus (COVID-19)—Global Market Conditions, Vaccines, Trials & Potential Treatments.”

Coronavirus COVID-19 Market ReportWhat are your thoughts on Athersys’ development of its MultiStem®therapy for the treatment of ARDS, a common cause of COVID-19 deaths? Share them in the comments below.

4.7/5 - (16 votes)

Filed Under: Coronavirus (COVID-19) Tagged With: Coronavirus

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Darlene Raudabaugh says

    April 2, 2020 at 7:33 pm

    I think someone needs to investigate the SA article the author of which does not believe that the Phase 2 trial was successful. The stock price plummeted today because of that article.

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.